Skip to main content
SpringerLink
Log in

Moderne Ansätze für Botulinumtoxin in der ästhetischen Medizin

Zum Management von Mythen

Modern approaches to botulinum toxin applications in aesthetics

Managing the myths

  • Übersichten
  • Published:
Journal für Ästhetische Chirurgie Aims and scope

Zusammenfassung

Weltweit zeigt sich bei der Anwendung von Botulinumtoxin (BoNT) für ästhetische Behandlungen ein stetiger Anstieg. Auch wissenschaftliche Forschung und klinische Erfahrungen konnten in den vergangenen Jahren immense Zuwächse verzeichnen; viel ist inzwischen darüber gesichert, wie das Molekül den erwünschten Effekt erzielt. Doch gleichzeitig sind Mythen, scheinbare „Fakten“, generiert worden, um zu versuchen, einzelne BoNT-Produkte voneinander zu unterscheiden. In den meisten Fällen handelt es sich bei den Mythen um Marketingtaktiken, die nicht durch Tatsachen oder Forschung begründet sind. Der Review-Artikel analysiert diese Mythen sowie Produktdetails und -charakteristika, Diffusion und die Ausbildung neutralisierender Antikörper, ferner mögliche Beziehungen zwischen einzelnen Faktoren. Dargestellt wird die entscheidende Relevanz, welche die Anatomie des Gesichts für die erfolgreiche Anwendung von BoNT hat, und vermittelt werden Kenntnisse über die Zielstruktur von BoNT − die neuromuskuläre Endplatte.

Der Beitrag steht als englische Originalversion auf SpringerLink zur Verfügung (unter „Supplemental“).

Abstract

The application of botulinum toxin (BoNT) for aesthetic treatments has seen worldwide, consistent growth. The science and knowledge of BoNT has also greatly increased in recent years and much is now known about how the molecule functions to give the desired effects. But there has also been a simultaneous increase in myths, apparent “facts” created about the BoNT products which are attempts to distinguish them from each other. In most cases, these myths are related only to marketing activities and have no basis in fact or science. This review will analyse these myths, including product data and characteristics, diffusion, neutralising antibody formation, the apparent relationships between these and the key relevance of facial anatomy to the successful use of BoNT products, especially knowledge about the targets of BoNT—the neuromuscular junction.

The English full-text version of this article is available at SpringerLink (under “Supplemental”).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Abbasi NR, Durfee MA, Petrell K et al (2012) A small study of the relationship between abobotulinum toxin A concentration and forehead wrinkle reduction. Arch Dermatol 148:119–121

    Article  PubMed  Google Scholar 

  2. Ascher B, Rzany BJ, Grover R (2009) Efficacy and safety of botulinum toxin type A in the treatment of lateral crow’s feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 35:1478–1486

    Article  PubMed  CAS  Google Scholar 

  3. Ascher B, Zakine B, Kestemont P et al (2005) Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthet Surg J 25:365–375

    Article  PubMed  CAS  Google Scholar 

  4. Borodic G (2006) Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthal Plast Reconstr Surg 22:239–240

    Article  PubMed  Google Scholar 

  5. Carruthers A, Carruthers J, Cohen J (2007) Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg 33:S97–S104

    Article  PubMed  CAS  Google Scholar 

  6. Carruthers J, Carruthers A, Monheit GD et al (2010) Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes. Dermatol Surg 36(Suppl 4):2135–2145

    Article  PubMed  CAS  Google Scholar 

  7. De Almeida AT, De Boulle K (2007) Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 9 (Suppl 1):17–22

    Article  Google Scholar 

  8. De Boulle K (2008) Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids. J Cosmet Laser Ther 10:87–92

    Article  Google Scholar 

  9. De Boulle K, Fagien S, Sommer B et al (2010) Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction. Clin Interv Aging 5:101–118

    Google Scholar 

  10. Dressler D, Wohlfahrt K, Meyer-Rogge E et al (2010) Antibody-induced failure of botulinum toxin A therapy in cosmetic indications. Dermatol Surg 36:2182–2187

    Article  PubMed  CAS  Google Scholar 

  11. Eisele KH, Fink K, Vey M et al (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555–565

    Article  PubMed  CAS  Google Scholar 

  12. Fagien S, Carruthers JD (2008) A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures. Plast Reconstr Surg 122:1915–1925

    Article  PubMed  CAS  Google Scholar 

  13. Goodmurphy CW (1996) A comparative morphological study of two human facial muscles: the orbicularis oculi and the corrugator supercilii. Department of Anatomy. University of British Columbia, Vancouver, Canada, p 148

  14. Goodmurphy CW, Ovalle WK (1999) Morphological study of two human facial muscles: orbicularis oculi and corrugator supercilii. Clin Anat 12:1–11

    Article  PubMed  CAS  Google Scholar 

  15. Hexsel D, Brum C, Do Prado DZ et al (2012) Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol 67:226–232

    Article  PubMed  CAS  Google Scholar 

  16. Hexsel D, Dal’forno T, Hexsel C et al (2008) A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 34:52–59

    Article  PubMed  CAS  Google Scholar 

  17. Hexsel D, Zechmeister-Do-Prado D, Lima-Gaboa M et al (2009) A phase IV controlled randomized double-blind study on the anhydrotic action halos and muscle activity of two commercial preparations type A botulinum toxin administered to the upper third of the face. J Am Acad Dermatol 60(Suppl) (Abstract P3500)

  18. Isse NG, Elahi MM (2001) The corrugator supercilii muscle revisited. Aesthet Surg J 21:209–215

    Article  PubMed  CAS  Google Scholar 

  19. Janis JE, Ghavami A, Lemmon JA et al (2007) Anatomy of the corrugator supercilii muscle: part I. Corrugator topography. Plast Reconstr Surg 120:1647–1653

    Article  PubMed  CAS  Google Scholar 

  20. Janis JE, Ghavami A, Lemmon JA et al (2008) The anatomy of the corrugator supercilii muscle: part II. Supraorbital nerve branching patterns. Plast Reconstr Surg 121:233–240

    Article  PubMed  CAS  Google Scholar 

  21. Klein AW, Carruthers A, Fagien S et al (2008) Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 121:413e–422e

    Article  PubMed  Google Scholar 

  22. Kosowski TR, Mccarthy C, Reavey PL et al (2009) A systematic review of patient-reported outcome measures after facial cosmetic surgery and/or nonsurgical facial rejuvenation. Plast Reconstr Surg 123:1819–1827

    Article  PubMed  CAS  Google Scholar 

  23. Kranz G, Sycha T, Voller B et al (2006) Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions. Dermatol Surg 32:886–890

    Article  PubMed  CAS  Google Scholar 

  24. Lee SK (2007) Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 33:S105–S110

    Article  PubMed  CAS  Google Scholar 

  25. Park JI, Hoagland TM, Park MS (2003) Anatomy of the corrugator supercilii muscle. Arch Facial Plast Surg 5:412–415

    Article  PubMed  Google Scholar 

  26. Pickett A (2012) Immunogenicity issues related to botulinum toxins in clinical use cannot be answered by speculation about product characteristics. BioDrugs 27:83–84

    Article  Google Scholar 

  27. Pickett A (2012) Inability of speculation to explain dose effect differences between botulinum toxin products. Arch Facial Plast Surg 14:467–468

    Article  PubMed  Google Scholar 

  28. Pickett A (2012) Issues in aesthetic uses of botulinum toxins. PRIME, Prime Journals 88–91

  29. Pickett A, Caird D (2008) Comparison of type a botulinum toxin products in clinical use. J Clin Pharm Ther 33:327–328

    Article  PubMed  CAS  Google Scholar 

  30. Poulain B, Popoff MR, Molgo J (2008) How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 1:14–87

    Article  Google Scholar 

  31. Rzany B, Ascher B, Fratila A et al (2006) Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 142:320–326

    Article  PubMed  CAS  Google Scholar 

  32. Rzany B, Ascher B, Monheit G (2010) Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview. J Eur Acad Dermatol Venereol 24(Suppl 1):1–14

    Article  PubMed  CAS  Google Scholar 

  33. Rzany B, Dill-Muller D, Grablowitz D et al (2007) Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4103 treatments in 945 patients. Dermatol Surg 33:S18–S25

    Article  PubMed  CAS  Google Scholar 

  34. Rzany B, Fratila AA, Fischer TC et al (2013) Recommendations for the best possible use of botulinum neurotoxin type a (speywood units) for aesthetic applications. J Drugs Dermatol 12:80–84

    PubMed  CAS  Google Scholar 

  35. Stengel G, Bee EK (2011) Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines. Clin Interv Aging 6:281–284

    Article  PubMed  CAS  Google Scholar 

  36. Wollmer MA, De Boer C, Kalak N et al (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 46:574–581

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Der Autor ist Gründer und Leiter des Unternehmens Toxin Science Limited, Wrexham, England, und außerordentlicher Professor am Botulinum Research Center, UMASS Dartmouth, Dartmouth, USA. Ferner ist er Leiter der Entwicklungsabteilung von Q-Med AB, einer Unternehmenssparte von Galderma. Die im Text geäußerten Ansichten und Kommentare sind lediglich die des Autors und die von Toxin Science Limited. Der Text ist frei von Werbung.

Author information

Authors and Affiliations

  1. Toxin Science Limited, LL12 8DU, Wrexham, UK

    A. Pickett

Authors
  1. A. Pickett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Pickett.

Additional information

Diese Arbeit wurde erstmals beim Treffen der Gesellschaft für Ästhetische Chirurgie Deutschland in Freiburg im Oktober 2012 vorgestellt.

Zusatzmaterial online

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pickett, A. Moderne Ansätze für Botulinumtoxin in der ästhetischen Medizin. J. f. Ästhet. Chirurgie 6, 166–172 (2013). https://doi.org/10.1007/s12631-013-0248-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12631-013-0248-x

Schlüsselwörter

Keywords

Search

Navigation